Why the study?
Lipid management is crucial for secondary prevention after ACS, but many patients remain undertreated and do not attain guideline-recommended LDL cholesterol reduction.
This review highlights the critical need for optimal, evidence-based lipid management and early escalation of lipid-lowering therapy to reduce the high residual risk of recurrent ischemic events in ACS survivors.
Answers are grounded in this paper and cite their sources.
Residual ischemic risk post-ACS supports algorithm-guided lipid escalation; leaves open prospective validation of recommendations.
Despite many improvements in its prevention and management, acute coronary syndrome (ACS) remains a major cause of morbidity and mortality in the developed world. Lipid management is an important part of secondary prevention after ACS, but many patients currently remain undertreated and do not attain guideline-recommended levels of low-density lipoprotein cholesterol reduction. This review details the current state of evidence on lipid management in patients presenting with ACS, provides directions for identification of patients who may benefit from early escalation of lipid-lowering therapy, and discusses novel lipid-lowering medication that is currently under investigation in clinical trials. Moreover, a treatment algorithm aimed at attaining guideline-recommended low-density lipoprotein cholesterol levels is proposed. Despite important advances in the initial treatment and secondary prevention of ACS, ≈20% of ACS survivors experience a subsequent ischemic cardiovascular event within 24 months, and 5-year mortality ranges from 19% to 22%. Knowledge of the current state of evidence-based lipid management after ACS is of paramount importance to improve outcomes after ACS.
No takes yet. Share an insight, caveat, or question.
Claessen et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: